Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 25, 2022
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
[ Wed, May 25th 2022
] - WOPRAI
Tue, May 24, 2022
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
[ Tue, May 24th 2022
] - WOPRAI
Chris Shibutani Maintained (TRDA) at Hold with Decreased Target to $10 on, May 24th, 2022
Chris Shibutani of Goldman Sachs, Maintained "Entrada Therapeutics, Inc." (TRDA) at Hold with Decreased Target from $22 to $10 on, May 24th, 2022.
Chris, nor any peers, have made any analyst calls on TRDA in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30